This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Johnson & Johnson (JNJ): Today's Featured Drugs Loser

Johnson & Johnson ( JNJ) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day down 1.8%. By the end of trading, Johnson & Johnson fell 60 cents (-0.9%) to $64.74 on average volume. Throughout the day, 10.2 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 10.1 million shares. The stock ranged in price between $64.74-$65.29 after having opened the day at $65.19 as compared to the previous trading day's close of $65.34. Other company's within the Drugs industry that declined today were: Synergy Pharmaceuticals ( SGYP), down 20.9%, Alexza Pharmaceuticals ( ALXA), down 19.7%, Anika Therapeutics ( ANIK), down 17%, and Cadence Pharmaceuticals ( CADX), down 16.7%.

Johnson & Johnson engages in the research, development, manufacture, and sale of various products in the health care field worldwide. Johnson & Johnson has a market cap of $179.35 billion and is part of the health care sector. The company has a P/E ratio of 18.4, above the average drugs industry P/E ratio of 17.9 and above the S&P 500 P/E ratio of 17.7. Shares are down 0.4% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the positive front, Cormedix ( CRMD), up 16.7%, Opexa Therapeutics ( OPXA), up 15.1%, Aoxing Pharmaceutical Company ( AXN), up 13.9%, and Transition Therapeutics ( TTHI), up 10%, were all gainers within the drugs industry with Sequenom ( SQNM) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs